The combinations of atezolizumab (anti-PD-L1) with bosutinib (Abl-Src inhibitor) in CML is under phase 1-2 clinical trial (NCT04793399), and the combination of G-CSF (sargramostim) with nilotinib (BCR-Abl inhibitor) in ALL is under phase 3 clinical trial (NCT02611492) [76]. This evidence concerns the gene ABL1 and acute lymphoblastic leukemia.